More recent pharmacological studies in both mouse and zebrafish suggest that the link between ErbB2 inhibition and DCM is not directly linked to cardiomyocyte survival; rather that pharmacological inhibition of ErbB2/erbb2 (without combination treatment with anthracycline), can result in myofibril remodeling. The gene discussed is ERBB2; the disease is familial dilated cardiomyopathy.